NCT01964651View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-42165279 50 mg

JNJ-42165279 50 mg orally administered once daily for 10 days.

DRUG

JNJ-42165279 100 mg

JNJ-42165279 100 mg orally administered once daily for 10 days.

DRUG

JNJ-42165279 30 mg

JNJ-42165279 30 mg orally administered once daily for 10 days.

DRUG

Placebo

Matching placebo orally administered once daily for 10 days.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01964651 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants | Biotech Hunter | Biotech Hunter